Posted by Michael Wonder on 29 Dec 2023
Opdualag licensed for patients with advanced melanoma
27 December 2023 - The MHRA has today approved the advanced melanoma medicine Opdualag (nivolumab-relatlimab) for patients from the age of 12.
Opdualag has been authorised through Project Orbis, a global partnership between the MHRA, the Therapeutics Goods Administration in Australia, Health Canada, the Health Sciences Authority in Singapore, Swissmedic, Agência Nacional de Vigilância Sanitária in Brazil and Israel’s Ministry of Health, coordinated by the US FDA.
